HSBC raised the firm's price target on Novo Nordisk to DKK 300 from DKK 280 and keeps a Hold rating on the shares. In a sector note on Healthcare, HSBC adjusted target prices on the prospects of the sector's relative outperformance potential for the second half of the year, noting that the Therapeutics space offering "attractive risk weighted returns," Tools "might be the best way to play a cyclical rally," and that MedTech is "cheap."
